March 2026

ALLR|EPS -$0.78|Rev $320,000|Net Loss $11.2M Allarity Therapeutics, Inc. reported a loss per share of $0.78 for the full year of 2025, as the clinical-stage precision medicine company continued advancing its pipeline of novel anti-cancer therapeutics. The company posted a net loss of $11.2M for the year while generating revenue of $320,000. The Allarity results reflect […]

MKC|EPS $0.66|Rev $1.87B|Net Income $1.02B Guidance adjusted $3.05 – $3.13|Stock $49.47  Solid beat. McCormick & Company, Incorporated (NYSE:MKC) delivered Q1 2026 adjusted EPS of $0.66, clearing expectations as the spice and seasonings giant posted revenue of $1.87B, up 16.7% from $1.61B in the year-ago quarter. The impressive top-line expansion demonstrates momentum across the company’s portfolio,

JILL|EPS -$0.02 vs $0.60 est (-103.3%)|Rev $138.4M|Net Loss $3.5M Stock $12.19  Significant Miss. J.Jill, Inc. (NYSE:JILL) delivered a disappointing fourth quarter, reporting an adjusted loss of $0.02 per share against Wall Street’s consensus estimate of $0.60 earnings per share, representing a miss by 103.3%. The apparel retailer generated $138.4M in revenue for the quarter, down

OSTX|EPS -$0.98|Net Loss $28.8M OS Therapies Incorporated posted a loss per share of $0.98 for the full year of 2025, as the clinical stage biopharmaceutical company continues to invest heavily in developing treatments for osteosarcoma and other solid tumors. The company reported a net loss of $28.8M for the year. The results reflect the capital-intensive

PVLA|EPS -$3.71|Net Loss $41.7M Palvella Therapeutics, Inc. reported a narrower loss for the full year of 2025, reflecting improved financial performance as the clinical-stage biopharmaceutical company advances its pipeline of therapies for serious and rare genetic skin diseases. The Wayne, Pennsylvania-based firm posted a loss per share of $3.71 for the year, a marked improvement

BOSC|EPS $0.12|Rev $12.6M|Net Income $819,000 B.O.S. Better Online Solutions Ltd. reported Q4 2025 diluted earnings of $0.12 per share, up 50.0% from $0.08 a year ago, as the technology solutions provider capitalized on growing demand for its logistics and supply chain services. The company generated $12.6M in revenue for the quarter, up 21.5% from $10.4M

INKT|EPS -$0.56|Net Loss $2.6M MiNK Therapeutics, Inc. reported a net loss per share of $0.56 for the fourth quarter of 2025, representing a 9.7% improvement from the $0.62 loss per share recorded in the same period a year earlier. The clinical-stage biopharmaceutical company, which focuses on developing allogeneic invariant natural killer T cell therapies, posted